Cargando…

EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR

Oncogenic alterations of epidermal growth factor receptor (EGFR) signaling are frequently observed in lung cancer patients with worse differentiation and poor prognosis. However, the therapeutic efficacy of EGFR-tyrosine kinase inhibitors (TKIs) is currently limited in selected patients with EGFR mu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jo, Ukhyun, Park, Kyong Hwa, Whang, Young Mi, Sung, Jae Sook, Won, Nam Hee, Park, Jong Kuk, Kim, Yeul Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012721/ https://www.ncbi.nlm.nih.gov/pubmed/24658031

Ejemplares similares

Clathrin‐mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild‐type EGFR non‐small cell lung cancer
por: Kim, Boyeon, et al.
Publicado: (2020)

Wnt5a Is Associated with Cigarette Smoke-Related Lung Carcinogenesis via Protein Kinase C
por: Whang, Young Mi, et al.
Publicado: (2013)

Pathways driving the endocytosis of mutant and wild-type EGFR in cancer
por: Hampton, Kaia K., et al.
Publicado: (2014)

Caveolin-1 Modulates Docetaxel-Induced Cell Death in Breast Cancer Cell Subtypes through Different Mechanisms
por: Kang, Jinho, et al.
Publicado: (2016)

ERRATUM: Caveolin-1 Modulates Docetaxel-Induced Cell Death in Breast Cancer Cell Subtypes through Different Mechanisms
por: Kang, Jinho, et al.
Publicado: (2019)

Predictive Efficacy of Low Burden EGFR Mutation Detected by Next-Generation Sequencing on Response to EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Carcinoma
por: Kim, Hye Sook, et al.
Publicado: (2013)

Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma
por: Kim, Seo Yun, et al.
Publicado: (2019)

Regulation of EGFR Endocytosis by CBL During Mitosis
por: Wee, Ping, et al.
Publicado: (2018)

EGFR endocytosis: more than meets the eye
por: Sapmaz, Aysegul, et al.
Publicado: (2023)

Piezo1 activates noncanonical EGFR endocytosis and signaling
por: Pardo-Pastor, Carlos, et al.
Publicado: (2023)

The pleckstrin homology domain of phospholipase D1 accelerates EGFR endocytosis by increasing the expression of the Rab5 effector, rabaptin-5
por: Park, Mi Hee, et al.
Publicado: (2015)

Detection of somatic variants and EGFR mutations in cell-free DNA from non-small cell lung cancer patients by ultra-deep sequencing using the ion ampliseq cancer hotspot panel and droplet digital polymerase chain reaction
por: Sung, Jae Sook, et al.
Publicado: (2017)

Polarised Clathrin-Mediated Endocytosis of EGFR During Chemotactic Invasion
por: Mutch, Laura Jane, et al.
Publicado: (2014)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

Tumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles
por: Kim, Jung Seok, et al.
Publicado: (2018)

Determination of EGFR Endocytosis Kinetic by Auto-Regulatory Association of PLD1 with μ2
por: Lee, Jun Sung, et al.
Publicado: (2009)

A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment
por: Kang, Jinho, et al.
Publicado: (2019)

Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR(WT), EGFR(T790M), and EGFR(L858R))
por: Abo Al-Hamd, Mahmoud G., et al.
Publicado: (2023)

Role of Endocytosis Proteins in Gefitinib-Mediated EGFR Internalisation in Glioma Cells
por: Cruz Da Silva, Elisabete, et al.
Publicado: (2021)

Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma
por: Tseng, Jeng-Sen, et al.
Publicado: (2014)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
por: Wang, Fen, et al.
Publicado: (2012)

Expanding the Therapeutic Window of EGFR-Targeted PE24 Immunotoxin for EGFR-Overexpressing Cancers by Tailoring the EGFR Binding Affinity
por: Jun, Sei-Yong, et al.
Publicado: (2022)

EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast
por: Hwangbo, Won, et al.
Publicado: (2013)

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
por: Park, Sehhoon, et al.
Publicado: (2020)

Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
por: Kwon, Byoung Soo, et al.
Publicado: (2017)

Discovery and Evaluation of Polymorphisms in the AKT2 and AKT3 Promoter Regions for Risk of Korean Lung Cancer
por: Sung, Jae Sook, et al.
Publicado: (2012)

Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer
por: Park, Silvia, et al.
Publicado: (2015)

The Association of EGFR Mutations with Stage at Diagnosis in Lung Adenocarcinomas
por: Cho, Jaeyoung, et al.
Publicado: (2016)

A multicenter, phase II trial of GC1118, a novel anti‐EGFR antibody, for recurrent glioblastoma patients with EGFR amplification
por: Choi, Seung Won, et al.
Publicado: (2023)

Oncogenic fusion of BCAR4 activates EGFR signaling and is sensitive to dual inhibition of EGFR/HER2
por: Bae, Kieun, et al.
Publicado: (2022)

The lysosome as a novel therapeutic target of EGFR-mediated tumor inflammation
por: Sung, Woo Jung, et al.
Publicado: (2022)

Discovery of Novel EGFR Inhibitor Targeting Wild-Type and Mutant Forms of EGFR: In Silico and In Vitro Study
por: Todsaporn, Duangjai, et al.
Publicado: (2023)

Therapeutic Efficacy of GC1118, a Novel Anti-EGFR Antibody, against Glioblastoma with High EGFR Amplification in Patient-Derived Xenografts
por: Lee, Kyoungmin, et al.
Publicado: (2020)

EGFR-Tyrosine Kinase Inhibitors Induced Activation of the Autocrine CXCL10/CXCR3 Pathway through Crosstalk between the Tumor and the Microenvironment in EGFR-Mutant Lung Cancer
por: Hong, Sook-hee, et al.
Publicado: (2022)

Effective Therapeutic Approach for Head and Neck Cancer by an Engineered Minibody Targeting the EGFR Receptor
por: Kim, Young Pil, et al.
Publicado: (2014)

Knockdown of HIP1 expression promotes ligand-induced endocytosis of EGFR in HeLa cells
por: Li, Dan, et al.
Publicado: (2017)

Involvement of SNX1 in regulating EGFR endocytosis in a gefitinib-resistant NSCLC cell lines
por: Nishimura, Yukio, et al.
Publicado: (2019)

Mechanism of p38 MAPK–induced EGFR endocytosis and its crosstalk with ligand-induced pathways
por: Perez Verdaguer, Mireia, et al.
Publicado: (2021)

Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line
por: Nishimura, Yukio, et al.
Publicado: (2008)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_8iitrgar8etvlp8o61bvtetnf6